10 Italian startups join U.S. biotech acceleration program in San Diego and Boston

Ten Italian biotech, pharma and health tech startups are spending four weeks in San Diego and Boston through the Italian Trade Agency's Global Startup Program. The cohort is pitching drug discovery, cancer therapy, healthcare AI and circular biotech to U.S. researchers, investors and potential partners as it targets international expansion.

Why it matters: - The 10-company cohort gives Italian startups direct access to two of the most important U.S. life sciences ecosystems. - The program is designed to help the startups sharpen their business models, meet investors and prepare for U.S. market entry. - The portfolio spans cancer therapies, drug discovery, healthcare AI and sustainable biotech, showing the range of Italian innovation being pushed into global markets.

What happened: - The Italian Trade Agency brought 10 Italian startups to San Diego and Boston for the Biotech & Pharma cohort of the seventh edition of its Global Startup Program. - The four-week program runs through Nov. 13. - Italian Consul General in Los Angeles Raffaella Valentini welcomed the startups on Oct. 22 as the U.S. residency began. - The cohort is coordinated by the Italian Trade Agency's Los Angeles office with the Consulate General of Italy in Los Angeles and Elpis Labs. - The program includes six industry-specific cohorts across international innovation hubs.

The details: - The startups will meet researchers, investors and industry partners in San Diego and Boston. - Program stops include BioLabs in San Diego's Torrey Pines biotech cluster, UC San Diego and the Salk Institute. - The Boston-area agenda includes LabCentral in Cambridge's Kendall Square and the Longwood Medical Area. - Meetings are planned with life sciences investors and industry experts, including representatives of Avalon Ventures. - The curriculum covers FDA regulatory pathways, intellectual property, fundraising and U.S. commercialization strategies. - Two Demo Days are scheduled for Nov. 5 in San Diego and Nov. 12 in Boston. - The program will give the startups a chance to pitch to potential partners and investors. - BrightMol Biotech has built a platform that identifies and validates promising drug molecules directly in living cells. - Kiran Biotech has developed a patented platform aimed at keeping therapeutic agents, including radiopharmaceuticals and antibodies, localized in tissues to reduce side effects. - Thera65 is developing a therapy to overcome drug resistance in certain solid tumors by selectively degrading a tumor-specific protein. - Nemira develops digital tools for communication and care coordination among families, caregivers and healthcare professionals supporting older adults, with an initial focus on dementia care and privacy-focused AI capabilities. - Ninacare uses an AI-powered platform to automate recruitment and human resources management for hospitals and care facilities. - QubiTale provides a way for hospitals to use patient data for research while protecting privacy. - V-Apps.cloud offers software that combines quality management, safety, training and regulatory compliance for highly regulated industries, including pharmaceuticals and medical devices. - Alma Serum develops dissolvable cosmetic membranes made from keratin nanofibers without water or preservatives. - AlphaFood develops food and protein products made with cricket flour, plus vertical farming systems and software for monitoring, traceability and standardized production. - Blueat, developed by Mariscadoras, turns invasive blue crabs into food products and uses processing byproducts to make sustainable biomaterials. - Blueat's model is framed as a circular economy approach to a marine pest problem.

Between the lines: - The cohort is part of a broader push by Italy to help startups internationalize through structured access to U.S. innovation hubs. - The mix of companies suggests the Italian pipeline is not limited to therapeutics; it also includes digital health, lab infrastructure and bio-based consumer products. - The presence of investors, research institutions and commercialization programming points to a focus on dealmaking, not just visibility. - The program's multi-city format in San Diego and Boston places the startups in front of both biotech research centers and venture capital networks.

What's next: - The startups will continue the four-week U.S. residency through Nov. 13. - The two Demo Days will serve as the main public pitch moments for investors and potential partners. - The companies are expected to leave with new contacts, feedback on U.S. market fit and clearer next steps for expansion. - The Global Startup Program will continue supporting international growth for selected Italian startups through overseas acceleration.

The bottom line: - Italy is using San Diego and Boston as launchpads to move promising biotech and health tech startups closer to U.S. commercialization and capital.